Soluble interleukin 2 receptors in patients with malignant lymphoma

D. S. Harrington, K. Patil, P. K. Lai, N. N. Yasuda, J. O. Armitage, S. H. Ip, D. D. Weisenburger, J. Linder, D. T. Purtilo

Research output: Contribution to journalArticlepeer-review

40 Scopus citations


We performed a retrospective analysis of serum interleukin 2 receptor (IL-2R) levels in a group of 35 patients with malignant lymphoma (ML; 13 T cell and 22 B cell) using a new enzyme immunoassay. Our objectives were to determine if elevated levels of soluble IL-2R occur in patients with active ML, whether serum IL-2R levels are prognostic, and whether prospective studies are warranted. Our preliminary data indicate that serum IL-2R levels correlate with disease activity and size of tumor, but not with grade or stage of the tumor. Five-year actuarial survival was 20% for patients with IL-2R levels greater than 1000 U/mL at any time during their course and 86% for patients who did not exceed that threshold. Furthermore, patients with IL-2R levels lower than 1000 U/mL were more likely to achieve a complete remission. Serum lactate dehydrogenase and uric acid levels did not show significant correlation with disease activity or prognosis. We conclude that serum IL-2R levels may have clinical and prognostic significance in patients with ML and that prospective studies are indicated.

Original languageEnglish (US)
Pages (from-to)597-601
Number of pages5
JournalArchives of Pathology and Laboratory Medicine
Issue number6
StatePublished - 1988

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology


Dive into the research topics of 'Soluble interleukin 2 receptors in patients with malignant lymphoma'. Together they form a unique fingerprint.

Cite this